358 related articles for article (PubMed ID: 37569894)
21. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
[TBL] [Abstract][Full Text] [Related]
22. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
23. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
Zhang X; Zhang H; Lan H; Wu J; Xiao Y
Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
[TBL] [Abstract][Full Text] [Related]
24. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
25. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
26. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
27. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
28. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
29. Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform.
Borrok MJ; Li Y; Harvilla PB; Vellalore Maruthachalam B; Tamot N; Prokopowitz C; Chen J; Venkataramani S; Grewal IS; Ganesan R; Singh S
Cancer Res Commun; 2022 Mar; 2(3):146-157. PubMed ID: 36874404
[TBL] [Abstract][Full Text] [Related]
30. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
32. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.
Yin L; Chen GL; Xiang Z; Liu YL; Li XY; Bi JW; Wang Q
Biomed Pharmacother; 2023 Jun; 162():114648. PubMed ID: 37023621
[TBL] [Abstract][Full Text] [Related]
33. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
34. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
36. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
39. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
[TBL] [Abstract][Full Text] [Related]
40. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
